The PTEN/PI3K/Akt and Wnt/β-catenin signaling pathways are involved in the inhibitory effect of resveratrol on human colon cancer cell proliferation

International Journal of Oncology

Volumn 45, Issue 1, 2014, Pages 104-112

  Liu, Ying Zi ^a,b   Wu, Ke ^a,b   Huang, Jun ^a,b   Liu, Yang ^a,b   Wang, Xin ^a,b   Meng, Zi Jun ^a,b   Yuan, Shuang Xue ^a,b   Wang, Dong Xu ^a,b   Luo, Jin Yong ^b   Zuo, Guo Wei ^b   Yin, Liang Jun ^b   Liang, Chen ^b   Deng, Zhong Liang ^b   Yang, Jun Qin ^a,b   Sun, Wen Juan ^a,b   He, Bai Cheng ^a,b  

^a Chongqing Munic Key Lab of Higher Educ   (China)

^b CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Anti proliferation; Colon cancer; PTEN PI3K Akt; Resveratrol; Wnt catenin

Indexed keywords

APOPTOSIS INDUCING FACTOR; BETA CATENIN; CRYSTAL VIOLET; FIREFLY LUCIFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RESVERATROL; WNT PROTEIN; ANTINEOPLASTIC AGENT; PTEN PROTEIN, HUMAN; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; FEMALE; FLOW CYTOMETRY; HCT116 CELL LINE; HISTOLOGY; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; WESTERN BLOTTING; WNT SIGNALING PATHWAY; ANIMAL; COLON TUMOR; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL PROLIFERATION; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; STILBENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902576168     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2392     Document Type: Article

References (42)

1. Brunagel G, Vietmeier BN, Bauer AJ, Schoen RE and Getzenberg RH: Identification of nuclear matrix protein alterations associated with human colon cancer. Cancer Res 62: 2437-2442, 2002.
2. Fey MF: Adjuvant therapy for colon cancer. Schweiz Med Wochenschr 130: 1760-1765, 2000 (In German).
3. Cragg GM, Grothaus PG and Newman DJ: Impact of natural products on developing new anti-cancer agents. Chem Rev 109: 3012-3043, 2009.
4. Mishra BB and Tiwari VK: Natural products: an evolving role in future drug discovery. Eur J Med Chem 46: 4769-4807, 2011.
5. Zou DM, Brewer M, Garcia F, et al: Cactus pear: a natural product in cancer chemoprevention. Nutr J 4: 25, 2005.
6. Konkimalla VB and Efferth T: Anti-cancer natural product library from traditional Chinese medicine. Comb Chem High Throughput Screen 11: 7-15, 2008.
7. Khan N, Afaq F and Mukhtar H: Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid Redox Signal 10: 475-510, 2008.
8. Korkina LG, De Luca C, Kostyuk VA and Pastore S: Plant polyphenols and tumors: from mechanisms to therapies, prevention, and protection against toxicity of anti-cancer treatments. Curr Med Chem 16: 3943-3965, 2009.
9. Das S, Santani DD and Dhalla NS: Experimental evidence for the cardioprotective effects of red wine. Exp Clin Cardiol 12: 5-10, 2007.
10. Jang M, Cai L, Udeani GO, et al: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997.
11. Gehm BD, McAndrews JM, Chien PY and Jameson JL: Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94: 14138-14143, 1997.
12. Bhat KPL, Kosmeder JW II and Pezzuto JM: Biological effects of resveratrol. Antioxid Redox Signal 3: 1041-1064, 2001.
13. Gulvady AA, Ciolino HP, Cabrera RM and Jolly CA: Resveratrol inhibits the deleterious effects of diet-induced obesity on thymic function. J Nutr Biochem 24: 1625-1633, 2013.
14. Fang JY, Li ZH, Li Q, Huang WS, Kang L and Wang JP: Resveratrol affects protein kinase C activity and promotes apoptosis in human colon carcinoma cells. Asian Pac J Cancer Prev 13: 6017-6022, 2012.
15. Lu R and Serrero G: Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol 179: 297-304, 1999.
16. Sheth S, Jajoo S, Kaur T, et al: Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS One 7: e51655, 2012.
17. Fouad M, Agha A, Merzabani MA and Shouman S: Resveratrol inhibits proliferation, angiogenesis and induces apoptosis in colon cancer cells: Calorie restriction is the force to the cytotoxicity. Hum Exp Toxicol 32: 1067-1080, 2013.
18. Yang HL, Chen WQ, Cao X, et al: Caveolin-1 enhances resveratrol-mediated cytotoxicity and transport in a hepatocellular carcinoma model. J Transl Med 7: 22, 2009.
19. Miura D, Miura Y and Yagasaki K: Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci 73: 1393-1400, 2003.
20. Liu HS, Pan CE, Yang W and Liu XM: Antitumor and immuno-modulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. World J Gastroenterol 9: 1474-1476, 2003.
21. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and Gonzalez-Baron M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204, 2004.
22. Mahimainathan L and Choudhury GG: Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase. J Biol Chem 279: 15258-15268, 2004.
23. Takeda K, Kanekura T and Kanzaki T: Negative feedback regulation of phosphatidylinositol 3-kinase/Akt pathway by overexpressed cyclooxygenase-2 in human epidermal cancer cells. J Dermatol 31: 516-523, 2004.
24. Chalhoub N and Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol 4: 127-150, 2009.
25. Waniczek D, Snietura M, Mlynarczyk-Liszka J, et al: PTEN expression profiles in colorectal adenocarcinoma and its precancerous lesions. Pol J Pathol 64: 15-20, 2013.
26. Franke TF, Kaplan DR, Cantley LC and Toker A: Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science 275: 665-668, 1997.
27. Zhang W, Zhang H, Wang N, et al: Modulation of β-catenin signaling by the inhibitors of MAP kinase, tyrosine kinase, and PI3-kinase pathways. Int J Med Sci 10: 1888-1898, 2013.
28. Robertson BW and Chellaiah MA: Osteopontin induces beta-catenin signaling through activation of Akt in prostate cancer cells. Exp Cell Res 316: 1-11, 2010.
29. He BC, Chen L, Zuo GW, et al: Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res 16: 2235-2245, 2010.
30. Stepanovic S, Vukovic D, Dakic I, Savic B and Svabic-Vlahovic M: A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods 40: 175-179, 2000.
31. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW and Vogelstein B: A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514, 1998.
32. Joe AK, Liu H, Suzui M, Vural ME, Xiao D and Weinstein IB: Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 8: 893-903, 2002.
33. Pal I and Mandal M: PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin 33: 1441-1458, 2012.
34. Lin MS, Huang JX, Chen WC, et al: Expression of PPARgamma and PTEN in human colorectal cancer: An immunohistochemical study using tissue microarray methodology. Oncol Lett 2: 1219-1224, 2011.
35. Garcia JM, Silva JM, Dominguez G, et al: Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype. Breast Cancer Res Treat 57: 237-243, 1999.
36. Aggarwal S and Chu E: Current therapies for advanced colorectal cancer. Oncology 19: 589-595, 2005.
37. Athar M, Back JH, Tang X, et al: Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224: 274-283, 2007.
38. Boocock DJ, Faust GE, Patel KR, et al: Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16: 1246-1252, 2007.
39. Vanamala J, Reddivari L, Radhakrishnan S and Tarver C: Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 10: 238, 2010.
40. Gweon EJ and Kim SJ: Resveratrol induces MMP-9 and cell migration via the p38 kinase and PI-3K pathways in HT1080 human fibrosarcoma cells. Oncol Rep 29: 826-834, 2013.
41. Hsu CP, Kao TY, Chang WL, Nieh S, Wang HL and Chung YC: Clinical significance of tumor suppressor PTEN in colorectal carcinoma. Eur J Surg Oncol 37: 140-147, 2011.
42. He BC, Gao JL, Luo X, et al: Ginsenoside Rg3 inhibits colorectal tumor growth through the down-regulation of Wnt/β-catenin signaling. Int J Oncol 38: 437-445, 2011.